Texto: 
asymptomatic right-sided abdominal mass.
6 weeks of neoadjuvant chemotherapy comprised of vincristine, dactinomycin, doxorubicin (dd4a) followed by right nephrectomy.
• initial study:
- large right-sided renal mass (12.2cm ap x 10.6cm trans x 14.1cm cc). predominantly hypodense w/ areas of heterogeneity.  possible cystic degeneration along superior border.
- classic “claw sign” demonstrating renal origination.
- significant mass effect on liver, pancreas, and inferior vena cava.
- non-opacification of right renal vein and mass effect on ivc limit evaluation for tumor thrombosis.
- right lower lobe ground glass opacity (3mm x 5mm).  ddx includes metastatic, atelectasis, or infection.

• after 6 weeks doxorubicin (dd4a) therapy:
- decrease in right renal mass size (7.3cm ap x 8.4cm trans x 11.7cm cc).
- increased calcification and heterogenicity of mass.
- continued mass effect on liver, adjacent ivc, and right renal vein.
- ivc and right renal vein grossly patent.
- resolution of previously noted right lower lobe lung mass.
- internal reproductive organs within normal limits for age.
wilms tumor
• wilms tumor
• neuroblastoma
• multilocular cystic nephroma
• mesoblastic nephroma
• renal cell carcinoma
30 month old girl with right-sided abdominal mass.
this case demonstrates the classic "claw sign" expected for tumor originating from the kidney.  also demonstrated the significant mass effect that wilms tumors can have on intra-abdominal organs and vessels.  finally, benefits on neoadjuvant therapy was appreciated with decreased tumor burden prior to tumor removal.


Keywords by value: 
- renal: 0.2810389550275198
- mass: 0.24626512935083938
- right: 0.21375074850908998
- wilms: 0.21226597827005933
- dd4a: 0.20620894129830217
- tumor: 0.20233500491275416
- ivc: 0.18780855223314502
- effect: 0.18090452961184236
- neoadjuvant: 0.1698285879589027
- claw: 0.16570732139353275
- nephroma: 0.16389800525594939
- doxorubicin: 0.16066329876954616
- trans: 0.15783406296581773
- vein: 0.138637857626542
- organs: 0.13300060841875475
- cc: 0.1248939119322842
- abdominal: 0.10578404048797616
- heterogenicity: 0.10310447064915108
- on: 0.09735797660191284
- classic: 0.09644365742752489
- dactinomycin: 0.09527038797029787
- origination: 0.09527038797029787
- ap: 0.09257298001855023
- comprised: 0.0906877433756196
- sign: 0.08926920726661704
- liver: 0.08895127819351349
- reproductive: 0.08610509878094133
- mesoblastic: 0.0838370800057607
- heterogeneity: 0.08033164938477308
- and: 0.07993386972066319
- burden: 0.07960222261259144
- multilocular: 0.0782710161020881
- cystic: 0.07765836392113895
- weeks: 0.07727844935702738
- vincristine: 0.07600299732690749
- limit: 0.07600299732690749
- of: 0.07570109511394911
- benefits: 0.07455819998860484
- lobe: 0.07451579499896734
- significant: 0.07444921355329893
- therapy: 0.07408648041723087
- 3mm: 0.07212696982516398
- finally: 0.0695322753544432
- 5mm: 0.0686946928073348
- originating: 0.0686946928073348
- lower: 0.06589033766141926
- nephrectomy: 0.06585428882855662
- glass: 0.06485344130912243
- ground: 0.06276092593976522
- hypodense: 0.06260285074438168
- vena: 0.06229318227118374
- cava: 0.06199177261620546
- grossly: 0.061844029437475904
- ddx: 0.06127164423387835
- pancreas: 0.06059466392346768
- degeneration: 0.05995595205968989
- neuroblastoma: 0.05923429044908522
- for: 0.05862273863195434
- patent: 0.05844675459141504
- expected: 0.05812534357977828
- appreciated: 0.05812534357977828
- atelectasis: 0.057409128021527187
- border: 0.05701935863026922
- predominantly: 0.05645880446745753
- opacity: 0.05609997457603179
- decrease: 0.05541478344634921
- demonstrating: 0.05316188466302988
- continued: 0.05282648342684891
- thrombosis: 0.052565149420320034
- resolution: 0.05230972177560996
- previously: 0.05175527965921891
- limits: 0.05094349139998365
- includes: 0.05013391925687917
- vessels: 0.05003022869261062
- removal: 0.049281465402058494
- tumors: 0.047415702330100756
- calcification: 0.046030027317883554
- chemotherapy: 0.04577925523763368
- kidney: 0.04529381040297397
- girl: 0.04522613240296059
- 30: 0.04398147548181204
- asymptomatic: 0.04389117785984766
- inferior: 0.043861238260271815
- areas: 0.043771892401864264
- possible: 0.04368324730250029
- size: 0.04365385276777617
- followed: 0.04353703320342276
- internal: 0.04345020415487505
- initial: 0.0432501601320956
- along: 0.04319364905321051
- study: 0.04299805617281772
- superior: 0.04191580669348321
- adjacent: 0.04179064270966048
- age: 0.040476044860824414
- decreased: 0.03993516691007854
- demonstrated: 0.03962264398750801
- evaluation: 0.03931853078216863
- lung: 0.03921895135182745
- month: 0.03921895135182745
- infection: 0.038944707929582455
- the: 0.03859339071112366
- carcinoma: 0.03856412677942223
- cell: 0.036880849595589904
- prior: 0.03607209477474305
- metastatic: 0.0353595663743573
- increased: 0.034863292848063825
- noted: 0.03418286287504677
- can: 0.033832766983461174
- case: 0.032389939697844476
- demonstrates: 0.032389939697844476
- large: 0.03230358059779333
- have: 0.03220720888165552
- after: 0.03127633522040694
- also: 0.030325694914176318
- within: 0.029693730746534686
- that: 0.027978350705994703
- by: 0.027378472618875483
- normal: 0.02632341050601119
- from: 0.02560547231943084
- with: 0.02524877550008037
- was: 0.0224690664623756
- or: 0.022428597061636846
- this: 0.02215367730138323
- old: 0.019081064623814085
- to: 0.01611782756274717
- in: 0.016038495648864497
